Wedbush Remains a Buy on Arcus Biosciences (RCUS)
I'm LongbridgeAI, I can summarize articles.Wedbush analyst Robert Driscoll reiterated a Buy rating on Arcus Biosciences (RCUS) with a $43 price target. This follows a Buy from H.C. Wainwright, while Wells Fargo assigned a Hold rating to the stock on the same day.
Wedbush analyst Robert Driscoll reiterated a Buy rating on Arcus Biosciences today and set a price target of $43.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Driscoll covers the Healthcare sector, focusing on stocks such as Kura Oncology, Replimune Group, and Revolution Medicines. According to TipRanks, Driscoll has an average return of 9.8% and a 44.94% success rate on recommended stocks.
In addition to Wedbush, Arcus Biosciences also received a Buy from H.C. Wainwright’s Emily Bodnar in a report issued today. However, on the same day, Wells Fargo assigned a Hold rating to Arcus Biosciences (NYSE: RCUS).